IN2014MN01442A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01442A
IN2014MN01442A IN1442MUN2014A IN2014MN01442A IN 2014MN01442 A IN2014MN01442 A IN 2014MN01442A IN 1442MUN2014 A IN1442MUN2014 A IN 1442MUN2014A IN 2014MN01442 A IN2014MN01442 A IN 2014MN01442A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
acceptable salt
diabetes
type
compound
Prior art date
Application number
Other languages
English (en)
Inventor
Shigeo Yamanoi
Hidenori Namiki
Yuichi Ochiai
Madoka Hoshino
Koji Matsumoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IN2014MN01442A publication Critical patent/IN2014MN01442A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IN1442MUN2014 2012-01-18 2013-01-17 IN2014MN01442A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012007840 2012-01-18
PCT/JP2013/050710 WO2013108800A1 (fr) 2012-01-18 2013-01-17 Dérivé de phénylazole substitué

Publications (1)

Publication Number Publication Date
IN2014MN01442A true IN2014MN01442A (fr) 2015-07-03

Family

ID=48799224

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1442MUN2014 IN2014MN01442A (fr) 2012-01-18 2013-01-17

Country Status (21)

Country Link
US (3) US9233958B2 (fr)
EP (2) EP2805941B1 (fr)
JP (2) JP6104181B2 (fr)
KR (1) KR20140113688A (fr)
CN (1) CN104159892A (fr)
AU (1) AU2013210394A1 (fr)
BR (1) BR112014017656A2 (fr)
CA (1) CA2861847A1 (fr)
CO (1) CO7020920A2 (fr)
ES (2) ES2640667T3 (fr)
HK (2) HK1200824A1 (fr)
IL (1) IL233682A0 (fr)
IN (1) IN2014MN01442A (fr)
MX (1) MX2014008790A (fr)
NZ (1) NZ627303A (fr)
PH (1) PH12014501646A1 (fr)
RU (1) RU2014133738A (fr)
SG (1) SG11201404026SA (fr)
TW (1) TWI551590B (fr)
WO (1) WO2013108800A1 (fr)
ZA (1) ZA201405108B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2640667T3 (es) 2012-01-18 2017-11-03 Daiichi Sankyo Company, Limited Derivados de 2-fenil-1,3-oxazol y 5-fenil-1,2,4-oxadiazol para el tratamiento de diabetes
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (fr) * 2015-12-17 2017-06-22 第一三共株式会社 Procédé de préparation d'un composé d'oxadiazole
EP3766879A1 (fr) * 2019-07-19 2021-01-20 Basf Se Dérivés de pytazole pesticides
CN111388471B (zh) * 2020-03-03 2021-01-12 牡丹江医学院 一种治疗胆囊炎的药物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Gpcr受容体作動薬としてのヘテロ環誘導体
JP2008500357A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Pparのモジュレーターとしての置換されたトリアゾールおよびこれらの調製方法
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
BRPI0616457A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-1,2 oxadiazolona com grupo fenila, bem como seu uso, composição farmacêutica compreendendo os mesmos e seu processo de preparação
GB0606913D0 (en) * 2006-04-06 2006-05-17 Prosidion Ltd Compounds
CA2646676A1 (fr) 2006-04-06 2007-10-18 Prosidion Limited Agonistes gpcr heterocycliques
EP2185544B1 (fr) * 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. Derives subtitues heterocycliques a liaison n de pyrrole, pyrazole, imidazole, triazole et tetrazole comme agonistes de recepteurs rup3 ou gpr119 utilises dans le traitement du diabete et des troubles metaboliques
CN101896481B (zh) 2007-10-16 2014-04-30 第一三共株式会社 嘧啶基二氢吲哚化合物
EP2241558A1 (fr) 2009-04-03 2010-10-20 Merck Serono SA Dérivés d'oxadiazole
WO2010119881A1 (fr) 2009-04-15 2010-10-21 第一三共株式会社 Composé d'indoline
EP2468737B1 (fr) * 2009-08-05 2013-10-30 Daiichi Sankyo Company, Limited Dérivé de sulfone
RU2536409C2 (ru) * 2009-08-05 2014-12-20 Дайити Санкио Компани, Лимитед Амидное производное
AU2011314712B2 (en) * 2010-10-14 2016-05-26 Daiichi Sankyo Company,Limited Acylbenzene derivative
JP5973440B2 (ja) 2011-07-29 2016-08-23 第一三共株式会社 N−ヘテロ環置換アミド誘導体
ES2640667T3 (es) 2012-01-18 2017-11-03 Daiichi Sankyo Company, Limited Derivados de 2-fenil-1,3-oxazol y 5-fenil-1,2,4-oxadiazol para el tratamiento de diabetes

Also Published As

Publication number Publication date
CO7020920A2 (es) 2014-08-11
TWI551590B (zh) 2016-10-01
KR20140113688A (ko) 2014-09-24
JP2017052800A (ja) 2017-03-16
ES2640667T3 (es) 2017-11-03
ES2602962T3 (es) 2017-02-23
HK1200824A1 (en) 2015-08-14
US20140357675A1 (en) 2014-12-04
CA2861847A1 (fr) 2013-07-25
AU2013210394A1 (en) 2014-08-14
NZ627303A (en) 2015-11-27
TW201335141A (zh) 2013-09-01
IL233682A0 (en) 2014-09-30
JPWO2013108800A1 (ja) 2015-05-11
HK1220448A1 (zh) 2017-05-05
EP3009433A1 (fr) 2016-04-20
US20160081993A1 (en) 2016-03-24
CN104159892A (zh) 2014-11-19
US9725438B2 (en) 2017-08-08
EP3009433B1 (fr) 2017-06-21
JP6104181B2 (ja) 2017-03-29
WO2013108800A1 (fr) 2013-07-25
US9233958B2 (en) 2016-01-12
AU2013210394A2 (en) 2014-10-16
EP2805941B1 (fr) 2016-08-17
ZA201405108B (en) 2015-10-28
RU2014133738A (ru) 2016-03-10
EP2805941A4 (fr) 2015-08-05
EP2805941A1 (fr) 2014-11-26
BR112014017656A2 (pt) 2017-06-27
PH12014501646A1 (en) 2014-10-13
SG11201404026SA (en) 2014-11-27
MX2014008790A (es) 2014-10-13
US20160090375A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
GEP201706719B (en) Pirfenidone treatment for patients with atypical liver function
NZ601121A (en) 5-alkynyl-pyrimidines
MY189483A (en) Purinone derivative
WO2013019561A8 (fr) Modulateurs de transport nucléaire et leurs utilisations
WO2012117000A8 (fr) 3-aminopyridines en tant qu'agonistes de gpbar1
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
MX2014015287A (es) Derivado del ester del acido heteroarilcarboxilico.
IN2014MN01442A (fr)
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX355261B (es) Derivado de indanosulfamida novedoso.
PH12014502802A1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IN2014DN05972A (fr)
WO2013155528A3 (fr) Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides
CY1116303T1 (el) Παραγωγο ακυλβενζολιου
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
MX2012001107A (es) Derivado de amida.
MX2014000929A (es) Derivados de amida sustituidos con n-hetero-anillo.
CA2836488C (fr) Methodes de traitement de l'obesite et/ou du syndrome metabolique
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
WO2012091425A3 (fr) Composition contenant, comme principe actif, un analogue de 4-hydroxytamoxifène ou un sel pharmaceutiquement acceptable de celui-ci, destinée à la prévention ou au traitement des maladies associées au syndrome métabolique
CA2863110A1 (fr) Derives de 1,2-pyridazine, 1,6-pyridazine ou pyrimidine-benzamide comme modulateurs de gpbar1
WO2011026193A8 (fr) Composés cytotoxiques
UA52171U (ru) Способ лечения дезадаптации сердечно-сосудистой системы у новорожденных с синдромом аспирации мекония
TH153171A (th) อนุพันธ์เฟนิแลโซลซึ่งถูกแทนที่